1Annane D,Clair B,Salomon J.Managing toxic shocksyndrome with antibiotics.Expert Opin Pharmacother,2004,5(8):1701-1710.
2Llewelyn M.Human leukocyte antigen class Ⅱ haplotypes that protect against or predispose to streptococcal toxic shock.Clin Infect Dis,2005,41(Suppl 7):S445-S448.
3Hollm-Delgado MG,Allard R,Pilon PA.Invasive group A streptococcal infections,clinical manifestations and their predictors,Montreal,1995-2001,Emerg Infect Dis,2005,11(1):77-82.
4Norton R,Smith HV,Wood N,et al.Invasive group A streptococcal disease in North Queensland (1996-2001).Indian J Med Res,2004,119(Suppl):148-151
5Ekelund K,Skinhoj P,Madsen J,et al.Reemergence of emm1 and a changed superantigen profile for group A streptococci causing invasive infections:results from a nationwide study.J Clin Microbiol,2005,43(4):1789-1796.
6Mencarelli M,Corbisiero R,Padula MG,et al.Group A streptococcal infections:trend and strain emm typing in an area of central Italy,1985-2002.Epidemiol Infect,2005,133(6):1107-1111.
7Stevens DL.Rationale for the use of intravenous gamma globulin in the treatment of streptococcal toxic shock syndrome.Clin Infect Dis,1998,26(3):639-641.
9Chiang MC,Jaing TH,Wu CT,et al.Streptococcal toxic shock syndrome in children without skin and soft tissue infection:report of four cases.Acta Paediatr,2005,94(6):763-765.
10US Department of Health and Human Services,Public Health Service,Centers for Disease Control and Prevention.Case definitions for infectious conditions under public health surveillance.MMWR Recomm Rep,1997,46(RR-10):1-55.
